ESTRO 2023 - Abstract Book

S810

Monday 15 May 2023

ESTRO 2023

Conclusion No consensus for determining MATV is available based on the literature. Using our software tool with 9 SUV thresholding methods, we demonstrated that there is a large variation in MATVs and, moreover, that their predictive performance of survival differed. Identifying the most optimal segmentation method for outcome prediction with MATV is essential in patients with LBCL.

Poster Discussion: Lung 2

PD-0961 Postoperative IMRT Radiotherapy in resected NSCLC patients: a multicentre retrospective analysis V. Nardone 1 , A. Bruni 2 , D. Franceschini 3 , S. Vagge 4 , M. Sepulcri 5 , A. Cappelli 6 , E. D'Angelo 7 , G. De Marco 8 , A. Angrisani 1 , M. Manetta 9 , M. Scricciolo 10 , C. Guida 11 , D. Aiello 12 , I. Fazio 13 , P. Borghetti 9 , S. Cappabianca 1 1 University of Campania "L. Vanvitelli", Department of Precision Medicine, Naples, Italy; 2 Radiotherapy Unit, University Hospital of Modena, Department of Oncology and Hematology, Modena, Italy; 3 Unit of Radiotherapy, IRCCS Humanitas Research Hospital, Department of Radiotherapy and Radiosurgery, Milan, Italy; 4 Radiation Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 5 Radiation Oncology Unit, Veneto Institute of Oncology IOV , Padua, Italy; 6 Radiotherapy Unit, University Hospital of Modena , Modena, Italy; 7 Radiotherapy Unit, University Hospital of Modena, Department of Oncology and Hematology, Modena, Italy; 8 Unit of Radiotherapy, Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy; 9 ASST Spedali Civili and University of Brescia, Radiation Oncology Department, Brescia, Italy; 10 Azienda ULSS 3 Venezia , UOC Radioterapia Oncologica, Venezia, Italy; 11 Ospedale del Mare, ASL Napoli 1 Centro, Radiotherapy Unit, Naples, Italy; 12 Casa di Cura Macchiarella, Radiation Oncology, Palermo, Italy; 13 Casa di Cura Macchiarellla, Radiation Oncology, Palermo, Italy Purpose or Objective Recently, LUNG-ART and J-PORT trial, both assessing the role of postoperative radiation therapy (PORT), have greatly changed the landscape of pN2 patients NSCLC patients undergoing surgery. In this scenario, the Italian Association of Radiotherapy and Oncology Lung Cancer study group has planned an observational multicenter trial aimed at evaluating toxicities of PORT in patients treated with modern techniques. Materials and Methods All acute and late toxicities (particularly cardiac, pulmonary and oesophageal) of PORT were retrospectively reported, analyzed and then related to clinical and dosimetric parameters. Collaterally, regional control, distant metastasis free survival and overall survival have been analyzed using Kaplan Meyer survival curves (significant when p < 0,05). Results Two hundred and twelve patients from 6 different centers have been included in the present analysis (142 males and 70 females, median age 68 years). One hundred-forty seven patients showed acute toxicity (69,3%), of whom 91 patients developed lung acute side effects (G1-G2 in 87 patients, G3 in 4 patients), 113 esophageal (G1-G2 in 112 patients, G3 in 1 patients) and finally only 4 cardiac (G1 in 2 and G3 in 2 patients). Sixty patients showed at least one late side effect (28,3%), mostly lung (43 patients G1-G2 and 1 G3) and esophageal (11 patients, all G1-G2); no late heart toxicity was reported.